Somaxon Pharma selects Paladin to commercialize Silenor
Silenor is a low-dose (3 mg and 6 mg) oral tablet formulation of doxepin, indicated to treat insomnia characterized by difficulties with sleep maintenance. As per the terms
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.
Luminex’s xTAG GPP detects hemolytic-uremic syndrome (HUS) causing Shiga-like toxin producing E. coli strain (STEC), besides detecting common disease-causing gastrointestinal pathogens, including viruses, bacteria and parasites, such as